Allele Capital

Allele Capital Strategic and financial advisory, merchant banking, and investment banking.

Allele Capital Partners is a merchant bank that provides venture capital and private equity financing to private and micro/small-cap public life science companies. Allele works in partnership with its clients to provide a suite of value-added services which include strategic advisory, proprietary capital and non-proprietary capital through Wilmington Capital Securities, LLC a Registered Broker-Dea

ler, Member FINRA, MSRB, and SIPC. All business executed through Wilmington Capital Securities is subject to FINRA and SEC Rules and Regulations. Whether through advisory or capital raising activities, Allele leverages its extensive proprietary network of advisers, C-Suite level management relationships and key opinion leaders (KOLs) for the benefit of its corporate and investment partners. Allele's Principals​ comprehensive experience in private-to-public and public venture process for small and micro-cap life sciences companies has resulted in significant shareholder equity and valuations of over $1 billion.

03/10/2026

Biotech Capital Markets – Week Ending March 6, 2026

Public markets drove the majority of capital raised last week, while private financings remained active, bringing total capital deployment to more than $3.5B across 23 deals

Key Highlights
• Total raised: $3.51 billion across 23 financings (average deal size: ~$152M)
• Public markets: $2.95 billion across 12 offerings
• Private markets: $553 million across 11 deals

Trends We’re Watching
• Public financings captured the vast majority of capital raised, reflecting continued strength in follow-on and public market funding
• Private deal activity remained balanced with public volume, signaling sustained venture participation despite smaller aggregate capital
• Larger average deal sizes suggest investors are concentrating capital into later-stage and high-conviction opportunities

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

02/09/2026

Biotech Capital Markets – Week Ending February 6, 2026

Public markets took the lead last week, delivering the majority of capital raised and pushing average deal sizes above the $100M mark.

Key Highlights
• Total raised: $1.72 billion across 17 financings (average deal size: ~$101M)
• Public markets: $1.41 billion across 11 offerings
• Private markets: $307 million across 6 deals

Trends We’re Watching
• Public financings accounted for more than 80% of weekly capital raised
• Fewer private deals closed, but overall averages remained elevated
• Capital deployment remains selective, favoring scale-ready assets early in 2026

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

02/02/2026

Biotech Capital Markets – Week Ending January 30, 2026

Public markets led capital deployment last week, while private activity remained steady, resulting in a solid $1.7B raised across 25 financings.

Key Highlights
• Total raised: $1.70 billion across 25 financings (average deal size: ~$89.6M)
• Public markets: $1.25 billion across 13 offerings
• Private markets: $733 million across 12 deals

Trends We’re Watching
• Public financings captured nearly three-quarters of total capital raised, driven by larger average round sizes
• Private deal volume stayed healthy, signaling continued venture engagement early in the year
• Overall activity reflects disciplined but confident capital allocation as 2026 momentum builds

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

01/27/2026

Biotech Capital Markets – Week Ending January 23, 2026

A quieter but balanced week, with private markets leading deal volume while public financings contributed slightly more capital overall.

Key Highlights
• Total raised: $1.70 billion across 19 financings (average deal size: ~$89.6M)
• Public markets: $863 million across 6 offerings
• Private markets: $839 million across 13 deals

Trends We’re Watching
• Private markets drove deal count despite fewer public issuances
• Public rounds were larger on average, keeping overall capital levels elevated
• Early 2026 activity suggests continued discipline paired with selective high-conviction deployments

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

01/14/2026

This week at JPM 2026 in San Francisco, we took capital markets visibility outside the conference walls.

Across Union Square and the surrounding JPM footprint, digital LED trucks featured healthcare companies engaging investors and industry leaders in real time — during the largest healthcare conference of the year.

For founders and investors alike, meaningful engagement starts with being visible, credible, and present.

If you’re still in San Francisco today, keep an eye out for the trucks and scan to learn more.

01/12/2026

Biotech Capital Markets – Week Ending January 9, 2026

Biotech funding kicked off the new year with strong momentum, as both public and private markets delivered multi-billion-dollar contributions in a high-volume week.

Key Highlights
• Total raised: $4.79 billion across 42 financings (average deal size: ~$114M)
• Public markets: $2.69 billion across 13 offerings
• Private markets: $2.10 billion across 29 deals

Trends We’re Watching
• Private markets led in deal count, while public markets edged ahead in total capital deployed
• Average deal size remained elevated, signaling early-year confidence and willingness to fund scale
• Broad participation across both markets suggests a strong capital reset heading into 2026

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

12/17/2025

Biotech Capital Markets – Week Ending December 12, 2025

A blockbuster close to the year, with public markets overwhelmingly driving capital deployment and pushing total weekly financing above $4.4B.

Key Highlights
• Total raised: $4.41 billion across 30 financings (average deal size: ~$147M)
• Public markets: $4.1 billion across 18 offerings
• Private markets: $303 million across 12 deals

rends We’re Watching
• Public markets dominated, accounting for more than 90% of total capital raised
• Average deal size surged to one of the highest levels of the year, driven by mega follow-ons
• Private activity slowed meaningfully, reflecting year-end selectivity and portfolio consolidation

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

12/09/2025

Biotech Capital Markets – Week Ending December 5, 2025

A balanced week across public and private markets, with total financings surpassing $2.1B as year-end momentum continues.

Key Highlights
• Total raised: $2.18 billion across 28 financings (average deal size: ~$77.8M)
• Public markets: $1.3 billion across 13 offerings
• Private markets: $852 million across 15 deals

Trends We’re Watching
• Public markets captured ~60% of total dollars raised, continuing a strong late-Q4 trend
• Private activity remained steady, with deal count slightly exceeding public issuances
• Investors appear to be accelerating deployments into year-end, with average deal size rising week-over-week

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

12/04/2025

Get acquainted with Andrew in this episode of Behind the Genes! One of our Directors here at Allele, Andrew is always up for a challenge. Learn more here!

11/26/2025

Biotech Capital Markets – Week Ending November 21, 2025

Private markets led the week in both deal count and capital raised, contributing more than half of the total $2.27B deployed across the sector.

Key Highlights
• Total raised: $2.27 billion across 34 financings (average deal size: ~$66.7M)
• Public markets: $978 million across 11 offerings
• Private markets: $1.28 billion across 23 deals

Trends We’re Watching
• Private markets outpaced public markets in both deal count and aggregate dollars raised
• Public financings dipped this week, driven mostly by smaller follow-ons
• Strong private deployment suggests investors remain confident in mid- and late-stage biotech entering the final stretch of the year

To receive this report weekly in your inbox, email us @ [email protected].
For more information & full disclosures, visit https://loom.ly/-n3ZxuM

Address

275 Commercial Boulevard Suite 333
Fort Lauderdale, FL
33308

Telephone

+15617063250

Website

Alerts

Be the first to know and let us send you an email when Allele Capital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category